Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21620977 | 0.89 | SIGMAR1 (0.60) | HRH3SIGMAR1POLBTSHRL3MBTL1 | |
| SCHEMBL18757040 | 0.86 | HRH3 (0.59) | HRH3SIGMAR1L3MBTL1MAPT | |
| SCHEMBL14426311 | 0.85 | HRH3 (1.00) | HRH3SIGMAR1POLBL3MBTL1SLC6A3 | |
| SCHEMBL25092917 | 0.84 | HRH3 (0.52) | HRH3SIGMAR1POLBMAPTNPSR1 | |
| SCHEMBL12880000 | 0.83 | HRH3 (0.78) | HRH3SIGMAR1L3MBTL1MAPTNPSR1 | |
| SCHEMBL14426314 | 0.83 | HRH3 (0.97) | HRH3SIGMAR1POLBL3MBTL1SLC6A3 | |
| SCHEMBL18923764 | 0.83 | HRH3 (0.97) | HRH3SIGMAR1POLBL3MBTL1SLC6A3 | |
| SCHEMBL178443 | 0.83 | NCF1 (0.66) | HRH3MAPT | |
| SCHEMBL13959223 | 0.82 | NCF1 (0.69) | HRH3SIGMAR1POLBTSHRL3MBTL1 | |
| SCHEMBL18808227 | 0.81 | L3MBTL1 (0.55) | HRH3SIGMAR1POLBTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| WO-2020011243-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-01-16 | — | — | WO | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8835443-B2 | Pyrimidine compound and medical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835443-B2 | Pyrimidine compound and medical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| WO-2008092049-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-31 | — | — | WO | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | HRH3 538/4885SIGMAR1 4602/4885POLB 2242/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | HRH3 92/4885SIGMAR1 38/4885POLB 4028/4885 |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | HRH3 824/4885SIGMAR1 2789/4885POLB 2504/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | HRH3 2130/4885SIGMAR1 3732/4885POLB 432/4885 |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | HRH3 2130/4885SIGMAR1 3732/4885POLB 432/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | HRH3 2130/4885SIGMAR1 3732/4885POLB 432/4885 |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | HRH3 2130/4885SIGMAR1 3732/4885POLB 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.